We are live on
!
Find out more
VA
VR Adviser Portfolio holdings
AUM
$2.68B
1-Year Est. Return
422.73%
This Fund
S&P 500
This Quarter
Est. Return
-13.87%
1 Year Est. Return
+422.73%
3 Year Est. Return
+1,447.09%
5 Year Est. Return
+3,249.52%
10 Year Est. Return
–
AUM
$1.46B
AUM Growth
-$452M
(-24%)
Cap. Flow
-$46.2M
Cap. Flow
% of AUM
-3.17%
Top 10 Holdings %
Top 10 Hldgs %
70.47%
Holding
41
New
3
Increased
5
Reduced
10
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
UPB
Upstream Bio Inc
UPB
|
+$51.3M |
| 2 |
Praxis Precision Medicines
PRAX
|
+$20.5M |
| 3 |
CDTX
Cidara Therapeutics
CDTX
|
+$12.4M |
| 4 |
enGene Therapeutics
ENGN
|
+$11.5M |
| 5 |
ORKA
Oruka Therapeutics
ORKA
|
+$4.88M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Edgewise Therapeutics
EWTX
|
+$26.7M |
| 2 |
TERN
Terns Pharmaceuticals
TERN
|
+$15.8M |
| 3 |
MRUS
Merus
MRUS
|
+$15.2M |
| 4 |
Aquestive Therapeutics
AQST
|
+$13.5M |
| 5 |
Taysha Gene Therapies
TSHA
|
+$12M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.48% |
| 2 | Financials | 0.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
APLT
26
DELISTED
Applied Therapeutics
APLT
| $8.55M | 0.59% |
9,990,591
+165,591
| +2% | +$1.04M |
|
|
PCSC
27
DELISTED
Perceptive Capital Solutions
PCSC
| $7.63M | 0.52% |
750,000
| – | – |
|
|
TERN
28
DELISTED
Terns Pharmaceuticals
TERN
| $5.97M | 0.41% |
1,077,090
-2,332,968
| -68% | -$15.8M |
|
|
29
Taysha Gene Therapies
TSHA
$1.68B
| $5.58M | 0.38% |
3,225,180
-5,774,820
| -64% | -$12M |
|
30
Trevi Therapeutics
TRVI
$2.59B
| $5.22M | 0.36% |
1,266,457
-2,156,199
| -63% | -$6.9M |
|
31
Zura Bio
ZURA
$516M
| $5.06M | 0.35% |
2,023,166
| – | – |
|
32
Century Therapeutics
IPSC
$364M
| $4M | 0.27% |
3,957,186
-1,432,073
| -27% | -$1.95M |
|
|
CASI
33
DELISTED
CASI Pharmaceuticals
CASI
| $2.79M | 0.19% |
987,259
| – | – |
|
34
Tenaya Therapeutics
TNYA
$161M
| $2.22M | 0.15% |
1,555,556
| – | – |
|
35
Tenax Therapeutics
TENX
$363M
| $1.29M | 0.09% |
208,333
| – | – |
|
|
CBIO
36
Crescent Biopharma
CBIO
$537M
| $747K | 0.05% |
+30,000
| New | +$818K |
|
37
Instil Bio
TIL
$48.3M
| $633K | 0.04% |
33,177
| – | – |
|
|
ADVM
38
DELISTED
Adverum Biotechnologies
ADVM
| – | – |
-1,467,048
| Closed | -$10.3M |
|
39
Arvinas
ARVN
$518M
| – | – |
-454,450
| Closed | -$11.2M |
|
40
Cabaletta Bio
CABA
$437M
| – | – |
-1,563,952
| Closed | -$7.38M |
|
|
41
Edgewise Therapeutics
EWTX
$4.13B
| – | – |
-1,000,000
| Closed | -$26.7M |
|
Similar funds
MMEA
WGI
TCAM
SFI
HC
CI
PCA
LP
VR Adviser's Q4 2024 Portfolio in Review
As of Q4 2024, VR Adviser held 41 positions worth $1.46B, down 24% from $1.91B the previous quarter. Its ten largest holdings account for 70% of the portfolio.
VR Adviser withdrew a net $46.2M in Q4 2024, closing 4 positions and reducing 10 holdings. Its most notable exit was Edgewise Therapeutics, an estimated $26.7M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Financials.
Against the trend, VR Adviser opened a new position in Upstream Bio Inc worth $37.7M.
- VR Adviser's largest Q4 2024 buy was Upstream Bio Inc: 2,295,319 shares worth $37.7M.
- VR Adviser added most to Praxis Precision Medicines in Q4 2024, an estimated $20.5M increase.
- VR Adviser's biggest Q4 2024 reduction was Terns Pharmaceuticals, cutting an estimated $15.8M.
- VR Adviser fully exited Edgewise Therapeutics in Q4 2024, selling an estimated $26.7M.
- VR Adviser's ten largest holdings make up 70% of its $1.46B portfolio in Q4 2024.
- VR Adviser opened 3 new positions and closed 4 in Q4 2024.
- VR Adviser's portfolio value fell 24% quarter-over-quarter to $1.46B.
Based on VR Adviser's 13F filing for Q4 2024, filed 14 Feb 2025.